<DOC>
	<DOCNO>NCT01493284</DOCNO>
	<brief_summary>The purpose study assess safety effectiveness SJM Portico Transcatheter Heart Valve SJM TAVI Transfemoral Transcatheter delivery system subject severe symptomatic aortic stenosis ( AS ) .</brief_summary>
	<brief_title>Assessment Of The St. Jude Medical Portico™ Transcatheter Aortic Valve Implant ( TAVI ) SJM TAVI Transfemoral Delivery System</brief_title>
	<detailed_description>Data collect baseline , procedure , discharge , 30 day post implant , 3 month post implant , 6 month post implant , 12 month post implant .</detailed_description>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . Subject give write study Informed Consent participation prior procedure . 2 . Subject ≥ 18 year age legal age host country . 3 . Subject 's aortic annulus diameter meet range indicated Instructions use measure echocardiogram ( echo ) CT conduct within past 90 day . 4 . Subject senile degenerative aortic stenosis echocardiography ( echo ) derive mean gradient &gt; 40mmHg jet velocity great 4.0 m/s initial valve area &lt; 1.0 cm2 ( aortic valve area index ≤ 0.6 cm2/m2 ) . ( Baseline measurement take echo within 30 day procedure ) . 5 . Subject symptomatic aortic stenosis demonstrate NYHA Functional Classification II great . 6 . Subject deem high operable risk suitable TAVI per medical opinion Subject Selection Committee ( See Section 3.1 definition Subject Selection Committee ) 7 . Subject 's predicted operative mortality serious , irreversible morbidity risk &lt; 50 % 30 day . 8 . In opinion Subject Selection Committee base upon angiographic measurement , subject suitable peripheral vessel aorta allow access 18 French delivery system . 9 . Subject structurally normal cardiac anatomy . 10 . Subject willing able comply require followup evaluation . 1 . Subject history cerebral vascular accident ( CVA ) transient ischemic attack ( TIA ) within past 6 month ( ≤180 day ) index procedure . 2 . Subject carotid artery disease require intervention . 3 . Subject evidence myocardial infarction ( MI ) within past 6 month ( ≤180 day ) index procedure . 4 . Subject hypertrophic cardiomyopathy . 5 . Subject native aortic valve congenitally unicuspid , bicuspid , quadricuspid noncalcified see echocardiography . 6 . Subject mitral tricuspid valvular regurgitation ( &gt; grade III ) moderate severe mitral stenosis . 7 . Subject aortic root angulation &gt; 70 degree ( horizontal aorta ) . 8 . Subject preexist prosthetic valve prosthetic ring position . 9 . Subject refuse blood transfusion surgical valve replacement . 10 . Subject leave ventricular ejection fraction ( LVEF ) &lt; 20 % . 11 . The subject document , untreated coronary artery disease ( CAD ) require revascularization . 12 . Subject severe basal septal hypertrophy . 13 . Subject percutaneous interventional invasive cardiac peripheral procedure ≤ 14 day index procedure . 14 . Subject history active endocarditis . 15 . Subject echocardiographic evidence intracardiac mass , thrombus , vegetation . 16 . Subject hemodynamic instability ( require inotropic support mechanical heart assistance ) . 17 . Subject acute pulmonary edema require intravenous diuretic therapy stabilize heart failure . 18 . Subject significant pulmonary disease . 19 . Subject significant chronic steroid use . 20 . Subject know hypersensitivity contraindication anticoagulant antiplatelet medication . 21 . Subject renal insufficiency evidence serum creatinine &gt; 3.0 mg/dL ( 265µmol/L ) endstage renal disease require chronic dialysis . 22 . Subject morbid obesity define BMI ≥ 40 . 23 . Subject 's iliac artery severe calcification , tortuosity ( &gt; two 90 degree bend ) , diameter &lt; 6mm , subject aortofemoral bypass . 24 . Subject ongoing infection sepsis . 25 . Subject blood dyscrasia ( leukopenia , acute anemia , thrombocytopenia , history bleeding diathesis , coagulopathy ) . 26 . Subject current autoimmune disease , opinion Principal Investigator precludes subject study participation . 27 . Subject significant aortic disease , include : aortic abdominal aneurysm ( AAA ) ≥ 4cm thoracic aneurysm ( define maximal luminal diameter 5 cm great ) mark tortuosity significant aortic arch atheroma narrow abdominal thoracic aorta severe tortuosity thoracic aorta . 28 . Subject preexist endovascular stent graft supra infrarenal aorta preexist stent graft ileofemoral artery . 29 . Subject active peptic ulcer gastrointestinal ( GI ) bleed within past 90 day prior index procedure . 30 . Subject currently participate another investigational drug device study . 31 . Subject require emergency surgery reason . 32 . Subject life expectancy &lt; 12 month . 33 . Subject medical , social psychological condition , opinion Subject Selection Committee , preclude subject study participation . 34 . Subject suffer dementia admit chronic care facility would fundamentally complicate rehabilitation procedure compliance followup visit . 35 . Subject know allergy contrast medium , nitinol alloy , porcine tissue , bovine tissue .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>aortic stenosis</keyword>
	<keyword>aortic valve stenosis</keyword>
	<keyword>valvular heart disease</keyword>
	<keyword>aortic valve replacement</keyword>
	<keyword>transcatheter aortic valve implantation</keyword>
	<keyword>TAVI</keyword>
</DOC>